NCT02188277 - Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Cerebral PalsySpastic Paraplegia and HemiparesisEquine and Equinovarus Foot Deformation

Interventions

DRUG

Xeomin

"Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius."

DRUG

Botox®

Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.

Trial Locations (3)

119602

"State Budget Institution of Health in Moscow Scientific and Practical Center of Pediatric psychoneurology Moscow Health Department", Moscow

119991

"Federal State Autonomous Institution Scientific Center of Children's Health of the Ministry of Health of the Russian Federation", Moscow

355017

"Federal State Budget Educational Institution of Higher Professional Learning Stavropol State Medical University of the Ministry of Health of the Russian Federation", Stavropol